Adult granulosa cell tumor (AGCT) is a sex cord stromal tumor (SCST) which constitutes 2-5% of all ovarian cancers. Initial treatment of early stage disease includes primary surgical resection with or without adjuvant treatment. Late stage disease and recurrent disease management involves multimodality treatment with surgical resection as the mainstay. Given the rarity of this tumor and its relative chemoresistance, future study is needed to better guide adjuvant treatment and individualize therapy for patients. Further evaluation of diagnostic and potential therapeutic implications involving FOXL2 mutations in AGCT is warranted.
predictor of recurrent disease with a hazard ratio (HR) of 3.58 and confidence interval (CI) of 1.10-9.03 [7] .
Counseling and treatment of diabetes mellitus has therefore been a complementary approach to disease prevention and AGCT recurrence risk (RR) modification.
Significant non-modifiable prognostic factors for recurrence include stage at diagnosis, tumor size, and mitotic index greater than four [8, 9] (Table 1) . Stage is considered the most important prognostic factor; patients with stage II disease have a greater than 7-fold increased risk for recurrence than patients with stage IA disease [8] . Mitotic index greater than 4 confers a 4.9x greater hazard for recurrence [8] . Residual disease after initial surgery [7, 10, 11] and residual disease after secondary debulking significantly affect overall survival (OS) [12] . 
Molecular Biology/Genetics/Pathology
More than 95% of ovarian AGCTs harbor a 402C>G missense somatic point mutation in the transcription factor FOXL2 gene which codes for granulosa cell differentiation and maintenance of ovarian function. This mutation causes a partial loss of apoptotic function in AGCT-derived cells [13] . In fact, the 402C>G mutation may reduce expression of GnRH receptors, making cells resistant to GnRH-induced apoptosis [14] . There has been some interaction studied between FOXL2, SMAD3 and GATA4 in regulating CCND2, which plays a role in cell cycle progression and granulosa cell proliferation [13] .
dissection is of limited value and typically not recommended, especially in suspected early stage 1A disease, as sex cord stromal tumors have a very low incidence of lymph node metastasis [29] . A recent study performed by Wilson et al further validated the importance of upfront surgical resection with optimal cytoreduction followed by adjuvant therapy if indicated [26] . This study reported patients who received neoadjuvant chemotherapy had a median recurrence almost two times earlier than those who underwent upfront surgical resection [26] . For young premenopausal patients desiring fertility sparing surgery, a unilateral salpingo-oophorectomy (USO) is feasible if disease is confined to one ovary (stage 1A) [27, 28] . Pelvic washings, omental sampling, and peritoneal biopsies are High risk features may include large tumor size (>10cm), poorly differentiated tumor, high mitotic index, tumor rupture, and stage 1C as these factors are associated with a higher risk of relapse [30] . Additional risk factors that may also warrant adjuvant therapy include obesity, diabetes, and residual disease [7, 26] . 
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Adjuvant chemotherapy was not significantly associated with DFS in early stage AGCT (p=0.193) [29] . A retrospective study of 40 patients with stage IC primary granulosa cell tumor of the ovary recently found no improvement in disease free survival with adjuvant chemotherapy [31] . The relative chemoresistance of this tumor and its predisposition for late recurrence makes the role of chemotherapy in early stage, low risk patients unclear.
There is variability in the cytotoxic treatment regimens for AGCT. The BEP regimen has been the most commonly used and widely studied regimen [32] . Several other regimens have been evaluated including cisplatin, vinblastine, bleomycin [33] , cisplatin, doxorubicin, cyclophosphamide [34] , taxanes with or without platinum [35] . Given the toxicity associated with chemotherapy, particularly with BEP, use of adjuvant treatment in early stage AGCT should involve a discussion with the patient regarding prognostic factors in the context of treatment toxicity.
Treatment of Advanced Stage and Recurrent AGCT
With metastatic or recurrent disease the mainstay of treatment is surgical cytoreduction with the goal to achieve no visible residual disease. In the setting of recurrent disease, a multi-modality approach is recommended. In nonresectable disease, radiation, chemotherapy, and hormonal therapy are reasonable approaches ( Figure 1 ). Most
AGCTs recur in the abdominal cavity and complete resection of recurrent tumor offers the best chance for survival [36] . Greater than 80% of recurrent patients can be optimally cytoreduced, though it is frequently technically challenging and can increase morbidity [10, 37] . Either paclitaxel/carboplatin or BEP is preferred for patients with recurrent AGCT of the ovary following complete surgical resection [28, 30] .
In a study of 57 patients, 84% of whom had sex cord stromal tumors, only 69% of patients with advanced stage disease and 51% of patients with recurrent disease remained progression free with the BEP regimen [35] . In inoperable recurrent disease, a response rate of only 22% was reported with moderate to severe toxicity [38] . A review of fifteen studies that assessed response rates to chemotherapy found in a total of 224 patients with residual or recurrent disease, a measured response rate of 50% was demonstrated (95% CI; 44-57%) [38] . A recent phase two study in patients with malignant stromal tumors evaluated paclitaxel (175mg/m2) over 3 hours as second line therapy [39] . Only one patient (3.2%) had a complete response and 8 patients (25.8%) had a partial response with this regimen [39] . Median PFS in this limited study group was 10.0 months with an OS of 73.6 months.
Myelosuppression was also a common side effect, impacting more than a third of participants [39] . Given the small number of complete responses, further study of single agent paclitaxel in the setting of recurrent malignant ovarian stromal tumors with measurable disease was not warranted [39] . 
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Data comparing the efficacy of paclitaxel/carboplatin to standard BEP is still lacking and an ongoing randomized phase 2 trial led by the Gynecological Oncology Group is evaluating this question [40] . One study demonstrated that at 4 years, the OS and event-free survival were 58% and 30% respectively with the BEP. Toxicity included 35% of patients with grade 4 neutropenia, 20% with febrile neutropenia, and 25% with a low bleomycin pulmonary toxicity [41] . Other studies have shown that while there is an overall response to the BEP regimen reported as high as 83%, its effect may be short lived with a mean PFS of only 14 months [42] . The improved toxicity profile associated with paclitaxel/carboplatin compared to BEP make it important to further elucidate if there is a difference in efficacy between these regimens. Prospective clinical trials are needed to further compare the efficacy of carboplatin and paclitaxel vs BEP ( Orteronel is a selective inhibitor of 17,20 lyase which suppresses sex hormone production *BEP = Belomycin Etoposide and Cisplatin; PFS = Progress Free Survival; SCT = sex cord tumors; OS = overall survival; AGCT = adult granulosa cell tumor; TRC102 = methoxyamine HCl. Chemotherapy in the recurrent setting appears to have clinical benefit (either complete remission, partial remission or stable disease after 6 months) [27, 29, 43, 44] . Other studies evaluating the role of chemotherapy in the recurrent setting have called into question the clinical benefit with recurrent AGCT with some studies suggesting no benefit [9] [10] [11] [12] . Limitations of these studies include the small number of enrolled patients, the various stages of disease, and the variation in chemotherapy regimens used.
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The role for radiation therapy with residual disease or in the recurrent setting remains unclear. Response rates are variable across the studies as imaging studies were not as precise at the time the original research was conducted [45] [46] [47] [48] [49] [50] [51] . With improvement in targeted radiation, further research is warranted in the role of radiation for treatment of oligometastatic disease.
Hormone Therapy/Targeted Therapy/Immunotherapy
The toxicity of BEP or carboplatin/paclitaxel regimens, including pulmonary fibrosis, myelosuppression, and neuropathy, demonstrate the importance of further evaluation of hormonal therapy and targeted agents. Hormonal therapy (HT) is a treatment option for recurrent metastatic or surgically unresectable AGCT [28] . Various agents that have been studied include medroxyprogesterone acetate, megestrol acetate, tamoxifen, aromatase inhibitors and GnRh agonists [28] . Progestins inhibit the production of pituitary gonadotropin, thereby reducing estrogen secretion and interfering with the amount of available estrogen [52] . In one small study, all 22 patients with AGCT were progesterone receptor (PR) positive, suggesting that one additional mechanism for the effectiveness of continuous progesterone is to downregulate receptors on the tumors themselves [53] . GnRH agonists inhibit gonadotropin release, thereby decreasing stimulation of granulosa cells [52] . The therapeutic role of aromatase inhibitors (AI) continues to be an area of active study. The proposed mechanism of action is that the FOXL2 missense point binds the aromatase promoter region and increases the activation of aromatase compared to wild type and endogenous estrogen production [56] . Recent data indicates the preservation of the c.402C>G FOXL2 mutation in recurrent AGCTs [57] . Two commonly prescribed AIs for HT are anastrozole
(1 mg daily) or letrozole (2.5 mg daily). Switching to a different AI when there is disease progression on the initial AI may provide some clinical benefit [58] .
Within the last decade, the development of anti-angiogenic and immunogenic agents may impact the treatment of AGCT. VEGF-A is a mediator of angiogenesis and is intimately involved with tumor growth, migration, and metastasis and is overexpressed in 94% of AGCTs [59] . Bevacizumab, is a monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). A recent study by Brown et al.
demonstrated that 77.8% of patients achieved stable disease with bevacizumab therapy alone [60] . One study showed that inhibin A and B appear to be markers of bevacizumab therapy response as they were significantly lower post-treatment in patients that did respond to bevacizumab [60] . Further study is needed to determine if inhibin A and B could be used as prognostic markers to select patients for response to anti-VEGF therapy. Additionally, 
Surveillance
Due to the late recurrence of this disease, long term follow-up is necessary. Monitoring inhibin A and B levels can be helpful in detecting recurrence. A study of 27 patients showed that serum inhibin levels increased to 10 times the upper limit of normal for postmenopausal women with evidence of disease [25] . Other studies have confirmed a 60-fold elevation in median inhibin B concentrations with active disease, reporting that disease usually becomes manifest within one year from marker elevation [62] . Inhibin B had a 89% sensitivity and 100% specificity rate and seemed to more accurately reflect disease status than inhibin A and thus may be the preferred method of follow-up [62] . Both inhibin B and AMH seem to predict earlier recurrence of disease compared to monitoring clinical symptoms and no evidence-based preference for either tumor marker exists [19, 20, 23] . Importantly AMH will not become elevated in epithelial ovarian cancers therefore making it an option to be used for follow up [23] .
Imaging should be limited to patients who are symptomatic or have concerning findings on physical exam. Serum tumor markers and a physical exam should be assessed every 2-4 months for the first 2 years followed by every 6 months thereafter [63] .
Survival
Early stage AGCT has an OS rate of 87 and 76% after 5 and 10 years [65] . In another study of 160 early stage patients, 5 and 10-year OS was 98.5 and 91.6% [26] . In comparison, OS for advanced stage disease is worse with 5-year survival rates between 22-50% [17] and 10-year survival rates for stage III and stage IV at 10% and 0%, respectively [65] . AGCT has been described as a very indolent clinical course well known for late recurrence with recurrence reported even 37 years after initial diagnosis [2] .
More than 70% of women with recurrence die from their disease [17] . Recurrence varies based on median follow-up period; 7% in 9.2 years, 21% in a median time of 57.6 months, 25% in 4-6 years; 32% in 12 years; 43% in 3.2 years [8, 9, 27, 65] . The pelvis is the most common site of recurrence followed by the liver, bowel and retroperitoneum [37] . Overall mortality rates of patients with recurrent AGCT was 30.3% with a median post-recurrent survival of 55.8 months (4.6-193.7 months) [36] . DFS alone contributed to OS in this study; if patients had DFS > 61.5 months, the risk of disease-related death was significantly decreased [36] . 
Conclusion
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